Out-of-hospital administration of IV glucose-insulin-potassium in patients with suspected ACS: the IMMEDIATE trial

Jun 18, 2012

Overview:The authors investigated whether the immediate intravenous (IV) administration of glucose, insulin and potassium (GIK) in the setting of emergency medical services would reduce ischemia-related arrhythmias and myocardial injury in suspected acute coronary syndromes. Compared with placebo, GIK administration was... more

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Jul 03, 2015

Overview:Introduction Statins inhibit cholesterol biosynthesis and decrease serum levels of low-density lipoprotein cholesterol (LDL-C) by inhibition of 3-hydroxy-3- methyl-glutaryl-coenzyme A reductase. Additional effects are widely recognized, including anti-inflammatory and anti-oxidant properties, improvement of endothelial function and angiogenesis1,2. Statins have primary... more

Qsymia Offers ‘Really Effective’ Weight Loss

Apr 28, 2017

Overview:By Professor Juan Tamargo, Madrid, Spain Qsymia is a formulation of two off-patent drugs already on the market: immediate-release phentermine and controlled-release topiramate. Phentermine is an amphetamine-like compound, currently licensed as a short-term weight loss agent due to its central... more

Influence of mitral regurgitation repair on survival in the Surgical Treatment for Ischemic Heart Failure (STICH) Trial

Jun 18, 2012

Overview:This study assessed the survival impact of functional mitral regurgitation (MR) in patients with ischemic heart disease and low ejection fraction (EF<35%). The authors also assessed the impact of adding mitral valve repair (MVrep) at the time of CABG on... more

First in Class ARNI, Valsartan/Sacubitril as a New Treatment of Chronic HFrEF

May 24, 2018

Overview:Sang Hong Baek MD, PhD, FACC, ESC Professor of Medicine (Cardiology), Seoul St. Mary’s Hospital, The Catholic University of Korea   Background The first approved ARNI (angiotensin receptor-nephrilysin inhibitor), valsartan/sacubitril, is a combination drug for use in chronic symptomatic heart... more

Women with Stable Angina Pectoris and No Obstructive Coronary Artery Disease: Closer to a Diagnosis

Women with Stable Angina Pectoris and No Obstructive Coronary Artery Disease: Closer to a Diagnosis

Nov 15, 2018

Overview:  Women have for many years been regarded as being at relatively low risk for the development of ischaemic heart disease (IHD).1,2 Recently this pattern has changed and cardiovascular disease (CVD) is now the leading cause of death for women in... more

Direct Oral Anticoagulants: A Quick Guide

Direct Oral Anticoagulants: A Quick Guide

Dec 06, 2018

Overview:  For more than 50 years, oral vitamin K antagonists (VKAs) were the choice of anticoagulant for the long-term treatment and prevention of arterial and venous thromboembolic events (VTE). VKA treatment is safe and effective, if a high time in... more

Pulmonary arterial hypertension in patients treated by dasatinib

May 17, 2012

Overview:Background Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder. The prognosis of CML has been transformed by tyrosine kinase inhibitors (TKIs), such as dasatinib. Knowledge Gap Although TKIs are usually well tolerated, these agents are nonetheless characterized by systemic toxicity... more

Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation MI patients with expected delays due to long-distance transfers

Jun 18, 2012

Overview:This investigates the safety and efficacy of a pharmaco-invasive reperfusion strategy utilizing half-dose fibrinolysis combined with transfer for immediate PCI in STEMI patients presenting to remote rural hospitals. The authors found no significant differences in 30-day mortality, stroke, major bleeding,... more

Retraction of the Jikei Heart Study

Oct 21, 2013

Overview:In 2007, the Lancet published the results of the Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study (1). According to the authors, the addition of the angiotensin... more

Page: